

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7641715

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
EMD SERONO RESEARCH & DEVELOPMENT INSTITUTE, INC.	02/12/2021
RECEIVING PARTY DATA	
Name:	MERCK HEALTHCARE KGAA
Street Address:	FRANKFURTER STRASSE 250
City:	DARMSTADT
State/Country:	GERMANY
Postal Code:	64293
PROPERTY NUMBERS Total: 2	
Property Type	Number
Patent Number:	11485786
Application Number:	18050817
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	571-458-7790
Email:	patent@gandmpatent.com
Correspondent Name:	GRUNEBERG AND MYERS PLLC
Address Line 1:	1775 TYSONS BLVD
Address Line 2:	5TH FLOOR
Address Line 4:	TYSONS, VIRGINIA 22102
ATTORNEY DOCKET NUMBER:	000615USCONT01-CONT02
NAME OF SUBMITTER:	ANGELA HENZ
SIGNATURE:	/Angela Henz/
DATE SIGNED:	11/11/2022
Total Attachments: 3	
source=000615USCONT01-02_Assignment-EMD Serono RDI Inc to Merck Healthcare KGaA#page1.tif	
source=000615USCONT01-02_Assignment-EMD Serono RDI Inc to Merck Healthcare KGaA#page2.tif	
source=000615USCONT01-02_Assignment-EMD Serono RDI Inc to Merck Healthcare KGaA#page3.tif	

PATENT ASSIGNMENT

WHEREAS, **EMD Serono Research & Development Institute, Inc.**, a corporation of Massachusetts, having a place of business at 45A Middlesex Turnpike, Billerica, MA 01821, USA, (hereinafter "ASSIGNOR"), is the owner by a lawfully executed Assignment of all rights, title and interest in an invention(s), which invention(s) is described in an application(s) for Letters Patent, which application(s) are listed in the attached Schedule as may be amended from time-to-time; and

Merck Healthcare KGaA, a corporation with general partners of Germany, having a place of business at Frankfurter Strasse 250, 64293 Darmstadt, Germany, (hereinafter "ASSIGNEE") have entered into an agreement ("Agreement") wherein all intellectual property developed under such Agreement shall be held in the name of ASSIGNEE.

Now, THEREFORE, pursuant to the above Agreement, the undersigned on behalf of ASSIGNOR has sold, assigned and transferred, and do hereby sell, assign and transfer unto ASSIGNEE, its lawful successors and assigns, the full, exclusive and worldwide right to the invention, and the entire right, title and interest in, to and under the application(s) and any and all Letters Patent(s) that may be granted on the application(s), any and all priority applications and Letters Patent thereof, any and all applications and Letters Patent claiming priority to the application(s), including any and all divisions or continuations thereof, any and all renewals, substitutes, reissues, reexaminations and extensions thereof, in the United States of America, in the territorial possessions of the United States of America, and equivalents thereto in any country foreign to the United States of America, including full right to claim for any such applications all benefits and priority rights under any applicable convention, the same to be held and enjoyed by ASSIGNEE, its lawful successors and assigns as fully and entirely as the same would have been held by ASSIGNOR had this assignment not been made.

ASSIGNOR hereby authorizes and requests the Commissioner of Patent and Trademarks of the United States of America and respective Patent Office officials in any country foreign to the United States of America to issue said Letters Patent to ASSIGNEE, and ASSIGNOR hereby further authorizes ASSIGNEE to apply for Letters Patent in ASSIGNOR name or in ASSIGNEE own name, as ASSIGNEE sees fit in its sole discretion, utilizing any benefits which may exist under any International Agreement, in any country.

ASSIGNOR hereby agrees for itself, its lawful successors, assigns and legal representatives to execute any lawful document and to testify as to any material fact or thing which ASSIGNEE, its lawful successors, assigns and legal representatives may deem necessary in order to secure unto ASSIGNEE, its successors and assigns the full right, title and interest in and to, and the full enjoyment of, the invention or any part thereof, the applications and any and all Letters Patent, the same to be done without any further consideration.

IN TESTIMONY WHEREOF, I hereby set my hand on behalf of **EMD Serono Research & Development Institute, Inc.**, this 12 day of February, 2021.

Signature: _____

Name and Title: Bernhard Seebach Asst. Gen. Prot. Counsel

Witnesses: I attest that on this day, the above person on behalf of **EMD Serono Research & Development Institute, Inc.** did sign above in my presence of his/her own free will.

Witness Signature: _____

Witness Name: Daniela Kissel

Date: 12th February 2021

Witness Signature: _____

Witness Name: HOLGER DORMANN

Date: 12th February 2021

IN TESTIMONY WHEREOF, I hereby set my hand on behalf of **Merck Healthcare KGaA**, this 24th day of February, 2021.

Signature: _____

Name and Title: Dr. Wolfgang Losert

Signature: _____

Name and Title: Dr. Arno Hartmann

Witnesses: I attest that on this day, the above person on behalf of **Merck Healthcare KGaA** did sign above in my presence of his/her own free will.

Witness Signature: _____

Witness Name: Heike Blimler

Date: February 24, 2021

Witness Signature: _____

Witness Name: Martina Bopp

Date: February 24, 2021

SCHEDULE

Application No.:	Country	Title	Filing Date	Inventor(s)
16/541,650	US	ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF FIBROSIS AND/OR FIBROTIC DISORDERS	August 15, 2019	Ilhan Celik Eike Staub Miriam Urban Sabine Raab-Westphal Eileen Samy Andrew Bender Georgianna Varrone Yin Wu Daigen Xu

Date: November 2, 2022